Shares of drug developer ArQule Inc. rose Tuesday after an RBC Capital Markets analyst started covering the stock with an “Outperform” rating based on its experimental cancer drug tivantinib.
Popular Posts:
- Depomed 3Q profit rises
- Analyst gauges financial loss from Novartis recall
- Analyst gauges financial loss from Novartis recall
- Infinity Pharma gains ground on analyst upgrade
- Infinity Pharma gains ground on analyst upgrade